1 Quick Injection.
1 Full Year*
of Flea and Tick Protection for Dogs.¹
Introducing Protection That Starts on Your Watch
Unleash the power of BRAVECTO® QUANTUM
Introducing the first ever, once-a-year injection for 12 months* of uninterrupted flea and tick protection.1
More Control
Ensures year-round1* coverage
Delivers 12 months* of uninterrupted flea and tick protection1
More Business Benefits
Supports you and your clinic
Strengthen client relationships and take control of compliance and revenue
More Convenience and Confidence
Makes year-long1* protection easy
1 simple injection gives clients 1 less thing to worry about
Take control of compliance
- Fleas and ticks disrupt your patients’ lives and threaten them with vector-borne diseasesâ€
- Leading veterinary parasitologists recommend year-round protection since it is impossible to predict every exposure to fleas and ticks2
- On average, owners only give 5.8 monthly doses of flea and tick protection a year3
- Without proper compliance, dogs are left at risk of disease
- With BRAVECTO QUANTUM, you can deliver 12 months* of guaranteed protection
Keep parasiticide revenue in your practice
- Writing scripts takes up valuable time, while administering BRAVECTO QUANTUM is quick and simple
- E-commerce marketplaces take revenue away from clinics
- One dose of BRAVECTO QUANTUM generates a year’s worth of parasiticide revenue for your clinic
The power of protection is in your hands
Discover the difference of year-round* flea and tick protection you control.
Kill fleas and ticks for a full year* in dogs 6 months of age or older with a single injection
Ctenocephalide felis
(cat flea)
Ixodes scapularis
(black-legged tick)
Rhipicephalus sanguineus
(brown dog tick)
Dermacentor variabilis
(American dog tick)
Amblyomma americanum*
(lone star tick)
Be proactive with year-round protection
Protecting against fleas and ticks for only 1 or 2 seasons a year leaves gaps in coverage.
86% of veterinarians recommend year-round flea protection.4
Fleas are well adapted to indoor environments.
- Central heating or carpeted floors may allow flea development to continue independent of seasonality6
81% of veterinarians recommend year-round tick protection.4
As tick populations increase, the need for tick prevention increases, too.5
- Every year yields new changes among tick populations2
- With changes in seasonality, tick activity becomes impossible to predict2
- Tick populations are expanding5
Experience a new level of certainty
BRAVECTO QUANTUM was demonstrated to be safe in dogs at 5X the recommended dose when administered every 4 months for a total of 6 injections.7

See the power of BRAVECTO QUANTUM in action
≥99.7% effective against adult fleas 24 hours post-infestation from one week through 12 months after treatment.7
Remained ≥94% effective against R sanguineus from Day 7 through Day 365.7
View results from numerous safety and efficacy studies.
BRAVECTO QUANTUM has been safely administered in numerous clinical studies to dogs of various ages, weights, and breeds, including mixed breeds.7
Learn more about this groundbreaking solution that helps ensure compliance and protection.
Find out moreImportant Safety Information
BRAVECTO (fluralaner) Chews for Dogs: The most commonly reported adverse reactions include vomiting, lethargy, diarrhea, anorexia and pruritus. In some cases, adverse events have been reported following use in breeding females. BRAVECTO Chews has not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. BRAVECTO Chews is not effective against lone star ticks beyond 8 weeks of dosing. Indicated for dogs 6 months of age and older. BRAVECTO 1-MONTH (fluralaner) Chews: The most commonly reported adverse reactions include itching, diarrhea, vomiting, decreased appetite, elevated ALT, lethargy, and weight loss. Not effective against lone star ticks in puppies less than 6 months of age. Indicated for dogs 8 weeks of age and older. BRAVECTO (fluralaner topical solution) for Dogs: The most commonly reported adverse reactions include vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash. BRAVECTO Topical Solution for Dogs has not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. BRAVECTO Topical Solution for Dogs is not effective against lone star ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. Indicated for dogs 6 months of age and older. BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension) for Dogs: The most commonly reported adverse reactions in a US field study included lethargy, decreased appetite, vomiting, diarrhea, elevated liver enzymes and pruritus. BRAVECTO QUANTUM is not effective against lone star ticks beyond 8 months of dosing. Indicated for dogs 6 months of age and older.
BRAVECTO (fluralaner topical solution) for Cats: The most commonly reported adverse reactions include vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO Topical Solution for Cats is not effective against American dog ticks beyond 8 weeks of dosing. BRAVECTO Topical Solution for Cats has not been shown to be effective for 12-weeks’ duration in kittens less than 6 months of age. The safety of BRAVECTO Topical Solution for Cats have not been established in breeding, pregnant and lactating cats. For topical use only. Avoid oral ingestion. Indicated for cats 6 months of age and older. BRAVECTO PLUS (fluralaner and moxidectin topical solution) for Cats: The most commonly reported adverse reactions include vomiting, hair loss, itching, diarrhea, lethargy, dry skin, elevated ALT, and hypersalivation. BRAVECTO PLUS has not been shown to be effective for 2 months in kittens less than 6 months of age. Use with caution in cats that are heartworm positive. The effectiveness of BRAVECTO PLUS to prevent heartworm disease after bathing or water immersion has not been evaluated. The safety of BRAVECTO PLUS have not been established in breeding, pregnant and lactating cats. Indicated for cats 6 months of age and older.
All BRAVECTO products contain fluralaner, which is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders.
References
- BRAVECTO QUANTUM. Product label. Merck Animal Health; 2025.
- The case for year-round flea and tick control. Companion Animal Parasite Council. Accessed March 27, 2024. https://capcvet.org/articles/the-case-for-year-round-flea-and-tick-control/
- Kynetec PetTrackâ„¢ MAT June 2024.
- Kynetec canine parasiticides brand health tracking–W4 Vets. August 8, 2023.
- 2023 Annual Pet Parasite Forecasts. Companion Animal Parasite Council. Accessed March 20, 2024. http://capcvet.org/articles/2023-annual-pet-parasite-forecasts/
- Dryden MW. Fleas in dogs and cats. Merck Veterinary Manual. April 2021. Updated July 2021. Accessed April 14, 2025.
https://www.merckvetmanual.com/integumentary-system/fleas-and-flea-allergy-dermatitis/fleas-in-dogs-and-cats - Freedom of Information Summary, NADA 141-599.
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen
Global